Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.00−0.06 (-1.48%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Taysha Gene Therapies's operating cash flow for the twelve months ending Jun 30, 2026 was -$132.19M. For fiscal 2025 it was -$93.09M. The highest annual figure on record is -$30.73M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$93.09M | – |
| FY2024 | Dec 31, 2024 | -$81.23M | – |
| FY2023 | Dec 31, 2023 | -$73.02M | – |
| FY2022 | Dec 31, 2022 | -$88.39M | – |
| FY2021 | Dec 31, 2021 | -$117.04M | – |
| FY2020 | Dec 31, 2020 | -$30.73M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$40.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$40.88M | – |
| Q4 FY2025 | Dec 31, 2025 | -$26.72M | – |
| Q3 FY2025 | Sep 30, 2025 | -$24.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.18M | – |
| Q1 FY2025 | Mar 31, 2025 | -$22.02M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.62M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.80M | – |
| Q4 FY2023 | Dec 31, 2023 | -$16.12M | -209.6% |
| Q3 FY2023 | Sep 30, 2023 | -$17.95M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.77M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.19M | – |
| Q4 FY2022 | Dec 31, 2022 | $14.71M | – |
| Q3 FY2022 | Sep 30, 2022 | -$28.81M | – |
| Q2 FY2022 | Jun 30, 2022 | -$33.35M | – |
| Q1 FY2022 | Mar 31, 2022 | -$40.94M | – |
| Q4 FY2021 | Dec 31, 2021 | -$40.26M | – |
| Q3 FY2021 | Sep 30, 2021 | -$31.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.82M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.04M | – |
| Q4 FY2020 | Dec 31, 2020 | -$19.85M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.72M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.47M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.70M | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
See a number that looks wrong?